Developments in virus-like particle-based vaccines for HIV

被引：1
|
作者：
Buonaguro, Luigi [1 ]
Tagliamonte, Maria [1 ]
Visciano, Maria Luisa [1 ]
Tornesello, Maria Lina [1 ]
Buonaguro, Franco M. [1 ]
机构：
[1] Ist Nazl Tumori Fond Pascale, Dept Expt Oncol, Mol Biol & Viral Oncol Unit, I-80131 Naples, Italy
来源：
EXPERT REVIEW OF VACCINES | 2013年 / 12卷 / 02期
关键词：
baculovirus expression vector system; broadly neutralizing antibody; conformational antigen presentation; HIV-VLPs; insect cells stable expression; vaccines; T-CELL RESPONSES; ANTIGEN-PRESENTING CELLS; ACTIVATE DENDRITIC CELLS; BLOOD MONONUCLEAR-CELLS; GENE-EXPRESSION PROFILE; TOLL-LIKE RECEPTORS; NEUTRALIZING ANTIBODIES; IMMUNE-RESPONSES; CLASS-I; ENVELOPE GLYCOPROTEINS;
D O I：
10.1586/ERV.12.152
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Virus-like particles (VLPs) hold great promise for the development of effective and affordable vaccines. VLPs, indeed, are suitable for presentation and efficient delivery to antigen-presenting cells of linear as well as conformational antigens. This will ultimately result in a crosspresentation with both MHC class I and II molecules to prime CD4(+) T-helper and CD8(+) cytotoxic T cells. This review describes an update on the development and use of VLPs as vaccine approaches for HIV.
引用
收藏
页码：119 / 127
页数：9
相关论文
共 50 条
  • [21] Adjuvant formulations for virus-like particle (VLP) based vaccines
    Cimica, Velasco
    Galarza, Jose M.
    [J]. CLINICAL IMMUNOLOGY, 2017, 183 : 99 - 108
  • [22] Role of the Gag-specific cytotoxic T lymphocytes during HIV pathogenesis: implications for the development of virus-like particle-based HIV-1 vaccines
    Wolf, HJ
    Notka, F
    Deml, L
    Leschonsky, B
    Walker, B
    Harrer, T
    Wagner, R
    [J]. 11E COLLOQUE DES CENT GARDES: RETROVIRUSES OF HUMAN AIDS AND RELATED ANIMAL DISEASES, 1998, : 179 - 185
  • [23] Versatile Virus-Like Particle Carrier for Epitope Based Vaccines
    Tissot, Alain C.
    Renhofa, Regina
    Schmitz, Nicole
    Cielens, Indulis
    Meijerink, Edwin
    Ose, Velta
    Jennings, Gary T.
    Saudan, Philippe
    Pumpens, Paul
    Bachmann, Martin F.
    [J]. PLOS ONE, 2010, 5 (03):
  • [24] Coming of age of virus-like particle vaccines
    Jennings, Gary T.
    Bachmann, Martin F.
    [J]. BIOLOGICAL CHEMISTRY, 2008, 389 (05) : 521 - 536
  • [25] Advances in Virus-Like Particle Vaccines for Filoviruses
    Warfield, Kelly L.
    Aman, M. Javad
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2011, 204 : S1053 - S1059
  • [26] The economics of virus-like particle and capsomere vaccines
    Chuan, Yap P.
    Wibowo, Nani
    Lua, Linda H. L.
    Middelberg, Anton P. J.
    [J]. BIOCHEMICAL ENGINEERING JOURNAL, 2014, 90 : 255 - 263
  • [27] Special Issue "Virus-Like Particle Vaccines"
    Vogel, Monique
    Bachmann, Martin F.
    [J]. VIRUSES-BASEL, 2020, 12 (08):
  • [28] Virus-like particle vaccines for mucosal immunization
    Estes, MK
    Ball, JM
    Crawford, SE
    ONeal, C
    Opekun, AA
    Graham, DY
    Conner, ME
    [J]. MECHANISMS IN THE PATHOGENESIS OF ENTERIC DISEASES, 1997, 412 : 387 - 395
  • [29] Freeze-Drying of a Capsid Virus-like Particle-Based Platform Allows Stable Storage of Vaccines at Ambient Temperature
    Aves, Kara-Lee
    Janitzek, Christoph M.
    Fougeroux, Cyrielle E.
    Theander, Thor G.
    Sander, Adam F.
    [J]. PHARMACEUTICS, 2022, 14 (06)
  • [30] Adjusted Particle Size Eliminates the Need of Linkage of Antigen and Adjuvants for Appropriated T Cell Responses in Virus-Like Particle-Based Vaccines
    Gomes, Ariane C.
    Flace, Anna
    Saudan, Philippe
    Zabel, Franziska
    Cabral-Miranda, Gustavo
    El Turabi, Aadil
    Manolova, Vania
    Bachmann, Martin F.
    [J]. FRONTIERS IN IMMUNOLOGY, 2017, 8
12345